Protein tyrosine phosphatase type IVA 3 is an enzyme that in humans is encoded by the PTP4A3gene.[1]
The protein encoded by this gene belongs to a small class of prenylated protein tyrosine phosphatases (PTPs). PTPs are cell signaling molecules that play regulatory roles in a variety of cellular processes. This class of PTPs contain a PTP domain and a characteristic C-terminal prenylation motif. Studies of this class of PTPs in mice demonstrated that they were prenylated proteins in vivo, which suggested their association with cell plasma membrane. Overexpression of this gene in mammalian cells was reported to inhibit angiotensin-II induced cell calcium mobilization and promote cell growth. Two alternatively spliced variants exist.[1]
Zeng Q, Hong W, Tan YH (1998). "Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1". Biochem. Biophys. Res. Commun. 244 (2): 421–7. doi:10.1006/bbrc.1998.8291. PMID9514946.
Dayton MA, Knobloch TJ (1998). "Multiple phosphotyrosine phosphatase mRNAs are expressed in the human lung fibroblast cell line WI-38". Receptors & signal transduction. 7 (4): 241–56. PMID9633825.
Zeng Q, Si X, Horstmann H, et al. (2000). "Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome". J. Biol. Chem. 275 (28): 21444–52. doi:10.1074/jbc.M000453200. PMID10747914.
Matter WF, Estridge T, Zhang C, et al. (2001). "Role of PRL-3, a human muscle-specific tyrosine phosphatase, in angiotensin-II signaling". Biochem. Biophys. Res. Commun. 283 (5): 1061–8. doi:10.1006/bbrc.2001.4881. PMID11355880.
Saha S, Bardelli A, Buckhaults P, et al. (2001). "A phosphatase associated with metastasis of colorectal cancer". Science. 294 (5545): 1343–6. doi:10.1126/science.1065817. PMID11598267.
Wang J, Kirby CE, Herbst R (2003). "The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis". J. Biol. Chem. 277 (48): 46659–68. doi:10.1074/jbc.M206407200. PMID12235145.
Pathak MK, Dhawan D, Lindner DJ, et al. (2003). "Pentamidine is an inhibitor of PRL phosphatases with anticancer activity". Mol. Cancer Ther. 1 (14): 1255–64. PMID12516958.
Zeng Q, Dong JM, Guo K, et al. (2003). "PRL-3 and PRL-1 promote cell migration, invasion, and metastasis". Cancer Res. 63 (11): 2716–22. PMID12782572.
Bardelli A, Saha S, Sager JA, et al. (2004). "PRL-3 expression in metastatic cancers". Clin. Cancer Res. 9 (15): 5607–15. PMID14654542.
Kozlov G, Cheng J, Ziomek E, et al. (2004). "Structural insights into molecular function of the metastasis-associated phosphatase PRL-3". J. Biol. Chem. 279 (12): 11882–9. doi:10.1074/jbc.M312905200. PMID14704153.
Kim KA, Song JS, Jee J, et al. (2004). "Structure of human PRL-3, the phosphatase associated with cancer metastasis". FEBS Lett. 565 (1–3): 181–7. doi:10.1016/j.febslet.2004.03.062. PMID15135076.
Kato H, Semba S, Miskad UA, et al. (2005). "High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases". Clin. Cancer Res. 10 (21): 7318–28. doi:10.1158/1078-0432.CCR-04-0485. PMID15534108.
Li J, Guo K, Koh VW, et al. (2005). "Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases". Clin. Cancer Res. 11 (6): 2195–204. doi:10.1158/1078-0432.CCR-04-1984. PMID15788667.
Polato F, Codegoni A, Fruscio R, et al. (2006). "PRL-3 phosphatase is implicated in ovarian cancer growth". Clin. Cancer Res. 11 (19 Pt 1): 6835–9. doi:10.1158/1078-0432.CCR-04-2357. PMID16203771.
Peng L, Jin G, Wang L, et al. (2006). "Identification of integrin alpha1 as an interacting protein of protein tyrosine phosphatase PRL-3". Biochem. Biophys. Res. Commun. 342 (1): 179–83. doi:10.1016/j.bbrc.2006.01.102. PMID16472776.
Rouleau C, Roy A, St Martin T, et al. (2006). "Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function". Mol. Cancer Ther. 5 (2): 219–29. doi:10.1158/1535-7163.MCT-05-0289. PMID16505094.